Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Neogen's EV/EBITDA was 35.9× on Nov 11, 2026, against 19.3× a year earlier. Over the last 5 years it ranged from 13.7× to 78.2×, with a median of 39.5×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 35.9× | +14.6 |
| 2024 | Dec 31, 2024 | 21.3× | −9.6 |
| 2023 | Dec 29, 2023 | 30.9× | +11.4 |
| 2022 | Dec 30, 2022 | 19.4× | −25.8 |
| 2021 | Dec 31, 2021 | 45.2× | +2.0 |
| 2020 | Dec 31, 2020 | 43.2× | +6.7 |
| 2019 | Dec 31, 2019 | 36.5× | +5.3 |
| 2018 | Dec 31, 2018 | 31.3× | −5.2 |
| 2017 | Dec 29, 2017 | 36.5× | −9.6 |
| 2016 | Dec 30, 2016 | 46.1× | +4.7 |
| 2015 | Dec 31, 2015 | 41.4× | −2.2 |
| 2014 | Dec 31, 2014 | 43.5× | +1.4 |
| 2013 | Dec 31, 2013 | 42.1× | +9.0 |
| 2012 | Dec 31, 2012 | 33.2× | +11.1 |
| 2011 | Dec 30, 2011 | 22.0× | −17.6 |
| 2010 | Dec 31, 2010 | 39.6× | – |
See a number that looks wrong?